DC-based vaccination

Finally, it has been shown that maturation of DCs is promoted by metabolized ginsenosides such as compound K. Takei et al (2004) showed that mature DCs differentiated with compound K enhance the differentiation of naive T cells toward the Thl t) e depending on lL-12 secretion, which clearly suggests that compound K has immunostimulatoty effects and that this compound is involved in the cancer preventive effects of ginseng and that compound K may be used on DC-based vaccines for cancer immunotherapy (Takei et al, 2004). 

Leamy VL, Martin T, Mahajan R, Vilalta A, Rusalov D, Hartikka J, Bozoukova V, Hall KD, Morrow J, Rolland AP, Kaslow DC, Lalor PA. Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines. Hum Vaccines 2006 2 113-8. 

Gilboa, E. 2007. DC-based cancer vaccines. J Clin Invest 117 1195-1203. 

V. Verez Bencomo, R. Roy, M. C. Rodriguez, A. Villar, V. Fernandez-Santana, E. Gareia, Y. Valdes, L. Heynngnezz, I. Sosa, E. Medina, in Carbohydrate-Based Vaccines, ed R. Roy, American Chemical Society, Washington, DC, 2008, ACS Symposium series 989, Chapter 4, 71. 

Larche M, Wraith DC Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005 11 S69-S76. 

Vilalta A, Mahajan RK, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P, Rolland A, Kaslow DC. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine evaluation of plasmid DNA biodistribu-tion/persistence and integration. Hum Gene Ther 2005 16 1143-50. 

U.S. Congress, Office of Technology Assessment, A Review of Selected Federal Vaccine and Immunization Policies Based on Case Studies of Pneumococcal Vaccine, OTA-H-96 (Washington, DC U.S. Government Printing Office, September 1979). 

Yusibov V, Hooper DC, Spitsin SV, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine, 2002 20(25/26) 3155-3164. 

Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., and Gabrilovich, D. 1. 2010. lngn-225 A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer Observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Jher, 10, 983-991. 

Crose BJ, Nichol K, Peterson DC, Grimm MB. Hospital-based strategies for improving influenza vaccination rates. J Fam Pract 1994 38 258-261. 

In another mouse model of cancer, IMO has been combined with a genetic vaccine targeting murine TERT (mTERT) based on DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) [101]. In this model, IMO induces dose-dependent cytokine secretion and activation of NK cells. Most importantly, vaccination of mice with IMO in combination with mTERT vaccine confers therapeutic benefits in tumor-bearing mice. Importantly, the therapeutic effect of the combination of mTERT vaccine and IMO correlates with increased NK, DC, and T-cell infiltration into the tumor microenvironment, suggesting the benefit of the combination of vaccine with IMO [101]. 

---